Table 6.

Complementary therapies in multisystemic inflammatory syndrome (MIS-C).

COMPLEMENTARY THERAPIES

✓Broad-spectrum antibiotic coverage pending the result of cultures (preferring association with clindamycin) •Proton pump inhibitor •Cardiovascular support •Acetylsalicylic acid at antiaggregating dosage: 3–5 mg/kg/day in a single administration per os for at least 6–8 weeks ✓Prophylaxis/antithrombotic therapy •In patients with thromboembolic risk factors or D-dimer elevation: Anti-thrombotic prophylaxis: low-molecular weight heparin 2 times/day (anti-X target activated 4 h from heparin somministration: 0.2–0.5 U/mL) In the case of venous thrombosis or coronary aneurysms *, systolic ventricular dysfunction: Anti-thrombotic therapy in medical judgment/reference hemostasis center * Coronary aneurysms are given treatment guidance according to the American Heart Association In case of acute renal failure and schistocytes, the hypothesis of acute uremic-hemolytic syndrome/thrombotic microangiopathy and the possible use of eculizumab iv should be considered